The independent source for health policy research, polling, and news.
KFF’s policy research provides facts and analysis on a wide range of policy issues and public programs.
KFF designs, conducts and analyzes original public opinion and survey research on Americans’ attitudes, knowledge, and experiences with the health care system to help amplify the public’s voice in major national debates.
KFF Health News is a national newsroom that produces in-depth journalism about health issues and is one of the organization’s core operating programs.
The brief provides a quick explainer of the prescription drug provisions in the Inflation Reduction Act signed into law on August 16, 2022 and presents new estimates on how many Medicare beneficiaries could be helped by those provisions.
Based on data from the KFF COVID-19 Vaccine Monitor, this poll finding explores attitudes among Hispanic Americans toward the coronavirus and a generational gap in willingness to get a potential vaccine.
This analysis examines COVID-19 vaccination rates among older adults in states that report these data at the person-level. It also looks at the change in vaccination rates between February 4 and February 23 among a subset of these states.
As of February 2021, there are three COVID-19 vaccines approved for emergency use in the U.S. and states are playing a central role in their timely distribution and prioritizing eligible populations. Because Medicaid covers for over 77 million enrollees, including groups disproportionately at risk of contracting COVID-19 as well as hard-to-reach groups, Medicaid agencies can be important partners for the public health agencies that are typically leading the state COVID-19 vaccination efforts. This brief provides…
Under the Medicare Drug Price Negotiation Program, the federal government negotiates prices with drug companies for certain high-cost drugs covered under Medicare Part B and Part D. This brief provides information about several key aspects of the Medicare drug price negotiation program, with a focus on the 2028 implementation year.
This Policy Watch examines how the 50 states and DC are defining “high-risk medical conditions” for COVID-19 vaccine prioritization, including whether they follow CDC’s recommendations or deviate in some way.
Debate about how many vaccinations are needed by when has been in the news. Drew Altman lays it out in his latest column.
Updated analysis of state-reported data as of February 1, 2021 on COVID-19 vaccinations, cases, and deaths by race/ethnicity is now available. Based on nearly half of states reporting vaccination data by race/ethnicity, Black and Hispanic people continue to receive smaller shares of vaccinations compared to their shares of cases and deaths and compared to their proportions of the total population. In all 23 states reporting data, Black people account for a smaller share of vaccinations compared…
Thirty-one percent of the public wants to “wait and see” how the COVID-19 vaccine is working for other people before getting vaccinated themselves. While they share a similar level of vaccine hesitancy, this group is not monolithic in their attitudes and beliefs. This brief examines how people with different partisan identities and those belonging to different racial and ethnic groups differ in their levels of concern about the vaccine and may respond differently to messages…
In his latest Axios column, Drew Altman looks at the challenge of vaccine hesitancy in rural America and its implications. One of them: a highly tailored outreach campaign is needed. “Addressing this hesitancy will require convincing rural Americans about the seriousness of the pandemic, and then that the vaccine is a way to protect them, their families and their way of life,” he said.
© 2026 KFF